Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RAPT logo RAPT
Upturn stock ratingUpturn stock rating
RAPT logo

RAPT Therapeutics Inc (RAPT)

Upturn stock ratingUpturn stock rating
$11.25
Last Close (24-hour delay)
Profit since last BUY29.01%
upturn advisory
Consider higher Upturn Star rating
BUY since 44 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: RAPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $22.33

1 Year Target Price $22.33

Analysts Price Target For last 52 week
$22.33 Target price
52w Low $5.66
Current$11.25
52w High $26.56

Analysis of Past Performance

Type Stock
Historic Profit -92.03%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 186.05M USD
Price to earnings Ratio -
1Y Target Price 22.33
Price to earnings Ratio -
1Y Target Price 22.33
Volume (30-day avg) 7
Beta 0.01
52 Weeks Range 5.66 - 26.56
Updated Date 08/15/2025
52 Weeks Range 5.66 - 26.56
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -14.8

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.09
Actual -0.65

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -46.24%
Return on Equity (TTM) -77.84%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 20267182
Price to Sales(TTM) 411.22
Enterprise Value 20267182
Price to Sales(TTM) 411.22
Enterprise Value to Revenue 677.37
Enterprise Value to EBITDA -10.73
Shares Outstanding 16537800
Shares Floating 6192742
Shares Outstanding 16537800
Shares Floating 6192742
Percent Insiders 0.42
Percent Institutions 95.5

ai summary icon Upturn AI SWOT

RAPT Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

RAPT Therapeutics, Inc. was founded in 2015. It is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for inflammatory diseases. They went public in 2020.

business area logo Core Business Areas

  • Drug Development: Focuses on discovering and developing oral small molecule therapies for inflammatory diseases, specifically targeting chemokine receptors such as CCR4 and other novel targets.
  • Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in various inflammatory conditions.

leadership logo Leadership and Structure

RAPT Therapeutics is led by Brian Wong, M.D., Ph.D., the President and CEO. The company has a board of directors overseeing its strategic direction and a management team responsible for day-to-day operations.

Top Products and Market Share

overview logo Key Offerings

  • FLX475: A CCR4 antagonist being developed for atopic dermatitis and other inflammatory conditions. Currently in clinical trials. There is no market share data available as the product is not yet approved. Competitors include companies developing treatments for atopic dermatitis such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.
  • RPT193: An oral small molecule CCR4 antagonist in clinical development for atopic dermatitis and asthma. Currently in clinical trials. There is no market share data available as the product is not yet approved. Competitors include companies developing treatments for atopic dermatitis such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with numerous companies developing therapies for inflammatory diseases. The demand for novel and effective treatments for these conditions is substantial.

Positioning

RAPT Therapeutics is positioned as an innovative company focused on developing oral small molecule therapies for inflammatory diseases, differentiating itself through its target specificity and oral delivery approach.

Total Addressable Market (TAM)

The total addressable market for inflammatory disease therapeutics is estimated to be in the tens of billions of dollars annually. RAPT Therapeutics is positioned to capture a portion of this market with its pipeline of drug candidates.

Upturn SWOT Analysis

Strengths

  • Novel drug development platform
  • Strong intellectual property portfolio
  • Experienced management team
  • Targeting large unmet medical needs

Weaknesses

  • Clinical trial risk
  • Limited revenue generation
  • Dependence on external funding
  • Small company size

Opportunities

  • Successful clinical trial outcomes
  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Acquisition by a larger company

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Failure of clinical trials
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • REGN
  • ABBV
  • PFE

Competitive Landscape

RAPT Therapeutics faces intense competition from larger, well-established pharmaceutical companies. Its competitive advantage lies in its novel drug development platform and oral small molecule approach.

Growth Trajectory and Initiatives

Historical Growth: RAPT Therapeutics has experienced growth in its research and development activities, as evidenced by the advancement of its drug candidates through clinical trials.

Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely depending on these factors.

Recent Initiatives: Recent initiatives include the advancement of FLX475 and RPT193 through clinical trials, as well as the identification and development of new drug candidates.

Summary

RAPT Therapeutics is a clinical-stage biopharmaceutical company with potential in developing oral therapies for inflammatory diseases. Its success hinges on positive clinical trial results and strategic partnerships. The company faces risks associated with drug development, competition, and funding. Their lack of current products on the market is impacting their market share. They are developing novel drugs and that could position them as a stronger company in the future.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Company website
  • Third-party market research reports
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About RAPT Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2019-10-31
CEO, President & Director Dr. Brian Russell Wong M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 61
Full time employees 61

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.